Radiopharm Theranostics Limited - American Depositary Shares (RADX)

In our clinic reviewing the RV-01 trial progress, dosing the first patient in the second cohort at the 70 mCi level following a clean safety recommendation is an encouraging step. Because RV-01 targets the B7-H3 immune checkpoint molecule across ten solid tumour types, watching how safety holds up at higher doses from the MD Anderson joint venture will dictate our view on its therapeutic window.

Looking at the upcoming extraordinary general meeting on 11 September 2026, sentiment on the trading desk is heavily focused on the dilution impact. While the company is securing shareholder approval for multi-component capital raises, placements, and new warrants including ADS Warrants at US$3.79, existing holders are forced to weigh long-term clinical potential against near-term equity overhang.

From a clinical research perspective, the RAD101 Phase 2b data showing 93% concordance between PET and MRI imaging gives a very solid foundation ahead of the 1 October 2026 FDA End-of-Phase 2 meeting. With FDA Fast Track Designation for distinguishing recurrent brain metastases, the upcoming alignment on pivotal Phase 3 trial designs with Siemens Healthineers partnerships in place is a massive operational milestone.

On our risk management desk, the core tension is between the operational catalysts and the balance sheet reality. Closing cash dropped to $4.1 million by June 30, 2026, creating an acute cash runway squeeze despite the debt-free headline. Even with six active clinical programs and positive Phase 2b data for RAD101, liquidity management remains the dominant short-term variable.

As a biotechnology equity analyst, my fundamental model highlights a persistent gap between pipeline success and valuation support. While the independent DSMC recommended advancing the 177Lu-RAD202 HEAT trial to Cohort 4 at 180mCi, the lack of profitability, negative P/E, and zero dividend yield leave the stock heavily reliant on clinical data readouts rather than traditional fundamental metrics.